The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2009
| Jurisdiction | UK Non-devolved |
| Citation | SI 2009/3135 |
| Year | 2009 |
2009 No. 3135
Dangerous Drugs, England And Wales
Dangerous Drugs, Scotland
The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2009
Made 30th November 2009
Laid before Parliament 2nd December 2009
Coming into force 23th December 2009
The Secretary of State, in exercise of the powers conferred by section 7(4) and (5) of the Misuse of Drugs Act 19711and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 7(7) of that Act, hereby makes the following Order:
Citation, commencement, interpretation and extent
1.—(1) This Order may be cited as the Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2009 and shall come into force on 23rd December 2009.
(2) In this Order “the 2001 Order” means the Misuse of Drugs (Designation) Order 20012.
(3) This Order extends to England, Wales and Scotland.
Amendment to the 2001 Order
2. In Part 1 of the Schedule to the 2001 Order—
(a) in paragraph 1(a), after “Bufotenine”, insert “1,4–Butanediol”;
(b) in paragraph 1(a), after “Fungus (of any kind) which contains psilocin or an ester of psilocin”, insert “Gamma–butyrolactone”;
(c) after paragraph 1(f), insert—
“(g)
“(g) 1–benzylpiperazine or any compound (not being a compound for the time being specified in Part II of this Schedule) structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways—
(i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;
(ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups;
(h)
(h) [2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone;
(i)
(i) 3–Dimethylheptyl–11–hydroxyhexahydrocannabinol;
(j)
(j) [9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate;
(k)
(k) 9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol;
(l)
(l) any compound structurally derived from 3–(1–naphthoyl)indole or 1H–indol–3–yl–(1–naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl...
To continue reading
Request your trial